Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers insights to how these can be overcome.
Biomarker exploration has been a crucial component of amyotrophic lateral sclerosis (ALS), explained Tania Gendron, PhD, assistant professor of neuroscience, Mayo Clinic. Data at the individual level has been lacking, Gendron noted, which creates additional challenges in patient care that clinicians and researchers are working to address.
This topic and more, including novel gene therapy research and influential policy, were explored at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference held in Dallas, Texas.
This transcript has been lightly edited; captions were auto-generated.
Transcript
What are some of the significant challenges faced by clinicians looking to translate biomarker discoveries into their clinical practice, and what steps can be taken to overcome these obstacles?
From my perspective as a researcher and those of others, the majority of studies that have been examining newly identified candidate biomarkers do so by evaluating biomarker potential utilities using population cohorts. As an example, multiple studies, including my own, have evaluated use of blood neurofilament and other biomarkers as prognostic biomarkers, meaning a biomarker that predicts disease severity and progression, or as a susceptibility risk biomarker, meaning that it informs impending symptom onset in asymptomatic individuals at genetic risk of ALS. However, biomarker studies comparing population cohorts, as we do, for instance, if you want to compare healthy controls to patients with ALS, those population cohorts provide more robust data at the group level than they do at the individual level. As such, there is a need to validate these biomarkers at the individual level if they are to be in fact, used in clinical practice.
Biomarker measurements and patient fluids are usually a part of using assays or tests. However, one of the challenges here in implementing the biomarker to the clinical practice is that there are large variations in the results when using different tests due to a lack of standard standardization among them. An avenue that is being pursued to overcome this challenge is the development of reference measurement procedures and of certified reference materials that we hope will ensure equivalent results between methods and tests across sites.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More